NCT02038699 - A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Biotech Hunter

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2016

Conditions

Advanced GlioblastomaAdvanced Colorectal CancerAdvanced Triple-negative Breast CancerAdvanced Non-small Cell Lung Cancer

Interventions

DRUG

ONC201

ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston